For Healthcare Professionals

Brentuximab Vedotin With Pembrolizumab in Metastatic Solid Tumors


About the study

This trial will find out whether brentuximab vedotin and pembrolizumab work together to treat different types of cancer. There will be several different types of cancer studied in the trial. The cancer must have spread to other parts of the body (metastatic). The study will also find out what side effects occur. A side effect is anything the treatment does besides treat cancer. This is a multi-cohort study.

Who can take part

You may be eligible to participate in the study if you meet the following criteria:


Inclusion Criteria

Participants must have

Metastatic squamous or nonsquamous non-small cell lung cancer (NSCLC) (without known targetable EGFR, ALK, ROS1, or BRAF mutations) who either

  1. a) have not yet received frontline therapy for metastatic disease and without prior exposure to anti PD-1/PD-L1 or
  2. b) are relapsed/refractory with progression on anti PD-1/PD therapy.
  3. Relapsed/refractory metastatic cutaneous melanoma (regardless of mutation status) with progression on a PD-1 inhibitor
  4. Metastatic head and neck squamous cell carcinoma (HNSCC) who have not yet received frontline therapy for metastatic disease and without prior exposure to a PD-1/PD-L1 inhibitor.
  5. Cohorts 1-4 only: Melanoma participants must be currently on PD-1 checkpoint inhibitor (CPI) therapy (e.g. nivolumab or pembrolizumab) or had their last dose of PD-1 CPI containing therapy as the last previous line of therapy within 90 days prior to enrollment; PD-1 CPI therapy must be the immediate prior line of treatment.

Cohorts 1-4 only: Participants must have progressed on treatment with an anti-PD-1 monoclonal antibody (mAb) administered either as monotherapy, or in combination with other CPIs or other therapies. PD-1 treatment progression is defined by meeting all of the following criteria.

Have received at least 2 doses of an approved PD-1 inhibitor.

Have demonstrated disease progression (PD) after a PD-1 inhibitor as defined by RECIST v1.1.

  1. Progressive disease has been documented within 90 days from the last dose of PD-1 inhibitor.
  2. Participants with melanoma will need iRECIST confirmation of progression with a second assessment at least four weeks after the initial date of progressive disease
  3. NSCLC participants on PD-1 inhibitor containing therapy for less than 90 days will need iRECIST confirmation of progression at least 4 weeks after the initial date of progressive disease
  4. Tumor tissue sample obtained within 3 months prior to enrollment is required, and no systemic anticancer therapy given after the sample was obtained.
  5. An Eastern Cooperative Oncology Group (ECOG) Performance Status score of equal or less than 1


Exclusion Criteria

  1. Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis.
  2. Prior immunosuppressive chemotherapy, any immunotherapy other than a PD-1 inhibitor within 4 weeks of first study drug dose.
  3. History of another malignancy within 3 years before the first dose of study drug or any evidence of residual disease from a previously diagnosed malignancy.
pin location

Study Locations

Enter your ZIP code/Postal code/PIN code to locate study sites near you:

How to Apply

Contact the study center to learn if this study is a good match for you.
Phone iconCall 866-333-7436Email iconEmail Study Center

Study’s details


Melanoma,Non-small Cell Lung Cancer,Squamous Cell Carcinoma of the Head and Neck

Age (in years)



Phase 2

Participants needed


Est. Completion Date

Sep 30, 2026

Treatment type



Seagen Inc. identifier


Study number


Understanding Clinical Trials

Get answers to your questions about clinical trials.What is a clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?


Sign up to save your favorites, 
receive newsletters, resources, and alerts 
about clinical trials related to your conditions of interest.